8-KEarnings & ResultsShareholder MattersExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 5, 2017)

Filed May 5, 2017For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on May 5, 2017, primarily to report its financial results for the first quarter ended March 31, 2017, via an accompanying press release (Exhibit 99.1). While the specific financial figures are not detailed within the 8-K itself, investors are directed to this press release for operational and financial condition updates. The filing also details the outcomes of the Company's 2017 Annual Meeting of Stockholders held on May 2, 2017. Key resolutions passed at the shareholder meeting included the re-election of four Class I directors, approval of the Second Amended and Restated 2009 Stock Incentive Plan, and the Amended and Restated 2004 Employee Stock Purchase Plan. Additionally, stockholders provided advisory approval for executive compensation and recommended an annual frequency for such votes. The appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2017 was also ratified.

Key Highlights

  • 1Alnylam Pharmaceuticals reported its Q1 2017 financial results on May 5, 2017, via a furnished press release (Exhibit 99.1).
  • 2The 2017 Annual Meeting of Stockholders took place on May 2, 2017, with 86,052,558 shares outstanding as of the record date.
  • 3Four Class I directors were re-elected by stockholders to serve until the 2020 annual meeting.
  • 4Stockholders approved the Company's Second Amended and Restated 2009 Stock Incentive Plan.
  • 5The Amended and Restated 2004 Employee Stock Purchase Plan also received stockholder approval.
  • 6An advisory vote on the compensation of named executive officers was approved, with a recommendation for annual frequency.
  • 7PricewaterhouseCoopers LLP was ratified as the independent auditor for the fiscal year ending December 31, 2017.

Frequently Asked Questions

The specific financial results for the quarter ended March 31, 2017, are detailed in the press release furnished as Exhibit 99.1 to this Form 8-K filing, dated May 5, 2017.

The key outcomes included the re-election of four Class I directors, approval of the 2009 Stock Incentive Plan and the 2004 Employee Stock Purchase Plan, advisory approval of executive compensation with a recommendation for annual voting frequency, and ratification of PricewaterhouseCoopers LLP as the independent auditor for FY2017.

No, the filing indicates that four Class I directors were re-elected, suggesting continuity rather than significant changes to the board composition as a result of this meeting.

Stockholders approved the compensation of the Company's named executive officers in a non-binding advisory vote, with a significant majority voting 'For' the compensation. They also recommended holding such advisory votes annually.